Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
| ▸ | GRM5 | P41594 | 4/20 | 0.59 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.56 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.56 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.56 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050389 | 0.86 | P2RY12 (0.61) | KCNJ6KCNJ3KCNJ5P2RY12MAPT | |
| SCHEMBL2084052 | 0.84 | KCNJ6 (0.59) | KCNJ6KCNJ3KCNJ5P2RY12MAPT | |
| SCHEMBL4306357 | 0.82 | PTPN1 (0.74) | PTPN1GRM5KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2080486 | 0.82 | MAPK14 (0.58) | KCNJ6KCNJ3KCNJ5P2RY12MAPT | |
| SCHEMBL16317149 | 0.81 | P2RY12 (0.56) | KCNJ6KCNJ3KCNJ5P2RY12MAPT | |
| SCHEMBL4049398 | 0.81 | PTPN1 (0.60) | PTPN1GRM5KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13576977 | 0.79 | PTPN1 (0.72) | PTPN1GRM5KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL14133258 | 0.77 | PTPN1 (0.83) | PTPN1GRM5KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL4111911 | 0.77 | TRPV1 (0.75) | MAPTSMN1; SMN2TRPV1 | |
| SCHEMBL2082551 | 0.76 | SMN1; SMN2 (0.58) | MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1836173-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | PTPN1 292/4885GRM5 1829/4885KCNJ6 4281/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | PTPN1 1275/4885GRM5 1190/4885KCNJ6 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.